1-3 of 3
Anna Franklin, MD
Close
Sort by
Journal Articles

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

Christopher J. Forlenza, MD, Nitya Gulati, MBBS, Audrey Mauguen, PhD, Michael J. Absalon, Sharon M. Castellino, MD MSc, Anna Franklin, MD, Frank G. Keller, MD, Neal Shukla, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-139480
Published: 2020
Journal Articles

Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A+AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)

Anna Franklin, MD, Marco Zecca, MD, Franca Fagioli, MD, Flavio Augusto Luisi, Gregory Song, Ajit Suri, E. Jane Leonard, Franco Locatelli
Journal: Blood
Blood (2018) 132 (Supplement 1): 1644.
https://doi.org/10.1182/blood-2018-99-112488
Published: 2018
Journal Articles

Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.

Deborah A. Thomas, MD, Michael Rytting, M.D., Susan O'Brien, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Anna Franklin, MD, Rebecca Garris, Farhad Ravandi, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 3084.
https://doi.org/10.1182/blood.V114.22.3084.3084
Published: 2009